Chongqing Quanxin Xiangsheng Biopharmaceutical

Chongqing Quanxin Xiangsheng Biopharmaceutical is a specialized biotechnology company and a key subsidiary of Mabpharm Limited, a prominent biopharmaceutical group listed in Hong Kong. Based in the Chongqing International Biological City, the company serves as a major research, development, and large-scale manufacturing hub for monoclonal antibodies and biosimilars. Its facilities are designed to meet international GMP standards, supporting the production of high-quality biologics targeting autoimmune diseases, oncology, and respiratory conditions. The company's portfolio includes several advanced assets, such as biosimilars for infliximab and omalizumab, which have successfully reached the commercial market in China. By leveraging advanced mammalian cell culture technologies, Chongqing Quanxin Xiangsheng aims to provide affordable and effective biological therapies to patients globally.